PHARMACORD acquired by PERMIRA

PharmaCord has been acquired by a company backed by Permira following a definitive agreement signed in June 2024. The transaction introduces new capital to PharmaCord while the existing management team, led by founder and CEO Nitin Sahney, retains operational control and a significant equity position. The investment is subject to customary regulatory approvals and is anticipated to close in the fourth quarter of 2024. Financial advisers to PharmaCord were Centerview Partners, with legal counsel provided by Willkie Farr & Gallagher; Permira’s advisers included Jefferies LLC and Leerink Partners, and its legal counsel was Skadden, Arps, Slate, Meagher & Flom LLP. Permira’s participation aligns with its strategy to expand in technology‑enabled healthcare services that support specialty pharmaceuticals. The firm identifies increasing therapeutic complexity and heightened demand for patient‑centric solutions as drivers of market opportunity, and views PharmaCord’s digital platform and extensive client relationships as complementary to its existing portfolio. By providing growth capital and leveraging its operational expertise, Permira aims to accelerate product development, broaden service offerings, and extend the company’s reach into additional therapeutic categories and geographic regions. Post‑closing, PharmaCord is expected to integrate additional technology resources, scale its analytics capabilities, and increase the volume of supported drug products. The partnership is projected to enhance operational efficiency through shared best practices and enable faster onboarding of new pharmaceutical clients. Expanded capital may also fund recruitment of specialized talent and the development of new adherence‑tracking tools, thereby strengthening the company’s position as a commercialization partner in the specialty drug market. The combined effort is anticipated to generate incremental revenue growth and improve patient outcome metrics across the serviced therapies.